Gina Mauro | Authors


Luspatercept Leads to Hemoglobin Increase in Patients With Non-Transfusion–Dependent Beta-Thalassemia

June 15, 2021

Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.

Pimitespib Shows Significant PFS Improvement in Advanced Refractory GIST

June 08, 2021

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

Pertuzumab Plus Trastuzumab Demonstrates Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 07, 2021

In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.